When a targetable genetic alteration is present, matching the alteration with the appropriate targeted therapy is associated with a survival benefit of 1.5 years, regardless of smoking history.
13-Dec-2017 11:05 AM EST Add to Favorites
Though most “low molecular weight polycyclic aromatic hydrocarbons” (LMW PAHs) have not been shown to cause cancer alone, the study shows that in common combinations, these chemicals can help to spark the disease.
30-Nov-2017 4:10 PM EST Add to Favorites
Many cancers depend on glucose consumption for energy, but good pharmacological targets to stop cancers’ ability to uptake and metabolize glucose are missing. CU Cancer Center study finally identifies a way to restrict the ability of cancer to use...
7-Nov-2017 11:05 AM EST Add to Favorites
CU Cancer Center study examines current RECIST guidelines in an effort to bring them up to speed with new complexities presented by the latest targeted therapies.
6-Nov-2017 4:35 PM EST Add to Favorites
In the Lab and in the Clinic, Alisertib with TAK-228 Excels Against Solid Tumors, Including Triple-Negative Breast Cancer
Two University of Colorado Cancer Center studies presented this weekend at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting show that using the drug alisertib along with the drug TAK-228 is more effective against triple-negative...
1-Nov-2017 11:05 AM EDT Add to Favorites
University of Colorado Cancer Center study being presented October 28 at the AACR-NCI-EORTC International Conference on Molecular Targets: By pairing an anti-EGFR drug with a “tail” that only activates the drug when it is very near tumor cells,...
24-Oct-2017 12:05 PM EDT Add to Favorites
University of Colorado Cancer Center study finds a genetic change called ALK-fusion in a patient sample of a melanoma subtype called mucosal melanoma. When researchers treated a tumor grown from this sample with the drugs crizotinib and ceritinib...
23-Oct-2017 2:05 PM EDT Add to Favorites
Some anti-cancer drugs are encapsulated to allow gradual release, spreading their effect over a longer time. For example, one formulation of the chemotherapy doxorubicin ( the FDA-approved drug Doxil®) encloses molecules of the drug in fatty...
18-Oct-2017 4:05 PM EDT Add to Favorites
27-Jul-2015 11:05 AM EDT
An education session presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 details the challenges of collaboration between oncologists and pathologists in the context of molecular testing patient tumor samples.
30-May-2014 4:00 PM EDT